1. Home
  2. RNW vs BEAM Comparison

RNW vs BEAM Comparison

Compare RNW & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNW
  • BEAM
  • Stock Information
  • Founded
  • RNW 2011
  • BEAM 2017
  • Country
  • RNW United Kingdom
  • BEAM United States
  • Employees
  • RNW N/A
  • BEAM N/A
  • Industry
  • RNW Electric Utilities: Central
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RNW Utilities
  • BEAM Health Care
  • Exchange
  • RNW Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • RNW 2.2B
  • BEAM 1.8B
  • IPO Year
  • RNW N/A
  • BEAM 2020
  • Fundamental
  • Price
  • RNW $6.21
  • BEAM $17.00
  • Analyst Decision
  • RNW Strong Buy
  • BEAM Strong Buy
  • Analyst Count
  • RNW 1
  • BEAM 11
  • Target Price
  • RNW $7.50
  • BEAM $50.50
  • AVG Volume (30 Days)
  • RNW 915.5K
  • BEAM 3.0M
  • Earning Date
  • RNW 06-04-2025
  • BEAM 05-06-2025
  • Dividend Yield
  • RNW N/A
  • BEAM N/A
  • EPS Growth
  • RNW N/A
  • BEAM N/A
  • EPS
  • RNW 0.04
  • BEAM N/A
  • Revenue
  • RNW $1,006,524,942.00
  • BEAM $63,518,000.00
  • Revenue This Year
  • RNW N/A
  • BEAM N/A
  • Revenue Next Year
  • RNW $38.75
  • BEAM $6.32
  • P/E Ratio
  • RNW $158.29
  • BEAM N/A
  • Revenue Growth
  • RNW N/A
  • BEAM N/A
  • 52 Week Low
  • RNW $5.15
  • BEAM $13.53
  • 52 Week High
  • RNW $7.49
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • RNW 55.37
  • BEAM 40.71
  • Support Level
  • RNW $6.03
  • BEAM $16.04
  • Resistance Level
  • RNW $6.23
  • BEAM $17.94
  • Average True Range (ATR)
  • RNW 0.25
  • BEAM 1.84
  • MACD
  • RNW 0.05
  • BEAM 0.26
  • Stochastic Oscillator
  • RNW 96.95
  • BEAM 44.24

About RNW ReNew Energy Global plc

ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: